ME02424B - Agensi koji vrše reverziju antikoagulanta - Google Patents
Agensi koji vrše reverziju antikoagulantaInfo
- Publication number
- ME02424B ME02424B MEP-2016-95A MEP201695A ME02424B ME 02424 B ME02424 B ME 02424B ME P201695 A MEP201695 A ME P201695A ME 02424 B ME02424 B ME 02424B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- subject
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 12
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 9
- 239000003130 blood coagulation factor inhibitor Substances 0.000 claims 5
- 229920000669 heparin Polymers 0.000 claims 5
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 229940127219 anticoagulant drug Drugs 0.000 claims 4
- 230000010100 anticoagulation Effects 0.000 claims 4
- 239000003055 low molecular weight heparin Substances 0.000 claims 4
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims 1
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 claims 1
- 108010029144 Factor IIa Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 229930003448 Vitamin K Natural products 0.000 claims 1
- 230000002429 anti-coagulating effect Effects 0.000 claims 1
- 229960003886 apixaban Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 229960003616 bemiparin Drugs 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 229940107792 certoparin Drugs 0.000 claims 1
- 229960004969 dalteparin Drugs 0.000 claims 1
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000622 edoxaban Drugs 0.000 claims 1
- 229960000610 enoxaparin Drugs 0.000 claims 1
- 238000002692 epidural anesthesia Methods 0.000 claims 1
- 229960001318 fondaparinux Drugs 0.000 claims 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960000899 nadroparin Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229960004762 parnaparin Drugs 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229960005496 reviparin Drugs 0.000 claims 1
- 229960001148 rivaroxaban Drugs 0.000 claims 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 claims 1
- 238000002693 spinal anesthesia Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229960005062 tinzaparin Drugs 0.000 claims 1
- 235000019168 vitamin K Nutrition 0.000 claims 1
- 239000011712 vitamin K Substances 0.000 claims 1
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 1
- 229940046010 vitamin k Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (23)
1. Jedinjenje formule II:ili njegova farmaceutski prihvatljiva so;gde su i L i L’ supstituisani ili nesupstituisani C1 do C10 alkilen lanac,gde su i M i M’ supstituisani C1 do C10 alkilen lanac i gde su i Y i Y’
2. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je jedinjenje predstavljeno formulom III: ili njegova farmaceutski prihvatljiva so.
3. Jedinjenje prema patentnom zahtevu 2, naznačeno time što je jedinjenje predstavljeno formulom IV: ili njegova farmaceutski prihvatljiva so, gde n je 3 do 5, m je 3 do 6 i G je izabran od -NH2 i OH.
4. Jedinjenje prema patentnom zahtevu 3, naznačeno time što G je amino.
5. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je jedinjenje predstavljeno formulom V ili njegova farmaceutski prihvatljiva so.
6. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je jedinjenje predstavljeno formulom VI ili njegova farmaceutski prihvatljiva so.
7. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je jedinjenje predstavljeno formulom VII ili njegova farmaceutski prihvatljiva so.
8. Jedinjenje prema patentnom zahtevu 1, naznačeno time što je jedinjenje predstavljeno formulom VIII ili njegova farmaceutski prihvatljiva so.
9. Farmaceutska kompozicija koja sadrži jedinjenje prema bilo kom od patentnih zahteva 1-8 i farmaceutski prihvatljiv nosač.
10. Farmaceutska kompozicija prema patentnom zahtevu 9, naznačena time što je kompozicija prilagođena (a) za enteralnu primenu; (b) za oralnu primenu; (c) za parenteralnu primenu; ili (d) za intravensku ili subkutanu primenu.
11. Jedinjenje prema bilo kom od patentnih zahteva 1-8 ili njegova farmaceutski prihvatljiva so za upotrebu u postupku potpune ili delimične reverzije antikoagulišućeg efekta inhibitora koagulacije kod subjekta kod koga postoji potreba za tim.
12. Jedinjenje za upotrebu prema patentnom zahtevu 11, naznačeno time što je inhibitor koagulacije izabran iz grupe koja se sastoji od nefrakcionisanog heparina, heparina niske molekulske težine (LMWH), inhibitora faktora IIa i inhibitora faktora Xa.
13. Jedinjenje za upotrebu prema patentnom zahtevu 12, naznačeno time što inhibitor koagulacije je inhibitor faktora Xa.
14. Jedinjenje za upotrebu prema patentnom zahtevu 13, naznačeno time što je inhibitor faktora Xa izabran iz grupe koja se sastoji od rivaroksabana, apiksabana, edoksabana i fondaparinuksa.
15. Jedinjenje za upotrebu prema patentnom zahtevu 11, naznačeno time što subjekat je (a) sisar; ili (b) čovek.
16. Jedinjenje za upotrebu prema patentnom zahtevu 11, naznačeno time što je potpuna ili delimična reverzija efekta antikoagulacije inhibitora koagulacije merena pomoću analize aktivnosti anti-faktora Xa.
17. Jedinjenje za upotrebu prema patentnom zahtevu 11, naznačeno time što, subjekat kod koga postoji poptreba za tim je subjekat kod koga je indicirana akutna ili planirana reverzija antikoagulacije.
18. Jedinjenje za upotrebu prema patentnom zahtevu 17, naznačeno time što (a) subjekat kod koga je indicirana akutna ili planirana reverzija antikoagulacije je subjekat koji pati od prekomerne doze antikoagulanta, subjekat koji pati od krvarenja, subjekat koji zahteva planiranu hiruršku intervenciju, subjekat koji se podvrgava invazivnoj ili neinvazivnoj proceduri koja zahteva biopsiju, subjekat koji se podvrgava proceduri u kojoj proceduralna greška može imati za rezultat krvarenje ako subjekat ostaje antikoagulisan, ili subjekat koji zahteva spinalnu ili epiduralnu anesteziju; ili (b) subjekat kod koga postoji potreba za tim je subjekat koji prima antikoagulaciju za prevenciju šloga, kardijačne hirurške i dijagnostičke postupke, srčane aritmije, prevenciju tromboze dubokih vena (DVT), plućne embolije ili generalno za prevenciju patoloških krvnih ugrušaka.
19. Jedinjenje za upotrebu prema patentnom zahtevu 12, naznačeno time što inhibitor koagulacije je LMWH, i što je LMWH izabran iz grupe koja se sastoji od bemiparina, certoparina, dalteparina, enoksaparina, nadroparina, parnaparina, reviparina i tinzaparina.
20. Jedinjenje za upotrebu prema patentnom zahtevu 11, naznačeno time što se jedinjenje ili njegova farmaceutski prihvatljiva so primenjuje u masenom odnosu doze od između oko 0.01:1 do oko 1000:1 jedinjenja ili njegove farmaceutski prihvatljive soli prema antikoagulantu, poželjno što se jedinjenje ili njegova farmaceutski prihvatljiva so primenjuje u masenom odnosu doze od oko 10:1 jedinjenja ili njegove farmaceutski prihvatljive soli prema antikoagulantu.
21. Jedinjenje za upotrebu prema patentnom zahtevu 11, naznačeno time što postupak sadrži primenu najmanje jednog dodatnog terapapeutskog sredstva; izborno što je najmanje jedno dodatno terapeutsko sredstvo vitamin K.
22. Dijagnostički kit koji sadrži jedinjenje prema bilo kom od patentnih zahteva 1-8.
23. Kit prema patentnom zahtevu 22, naznačen time što se kit koristi za određivanje koncentracije antikoagulanta u krvi.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161564559P | 2011-11-29 | 2011-11-29 | |
| US201261614292P | 2012-03-22 | 2012-03-22 | |
| US201261641698P | 2012-05-02 | 2012-05-02 | |
| US201261666291P | 2012-06-29 | 2012-06-29 | |
| PCT/US2012/066938 WO2013082210A1 (en) | 2011-11-29 | 2012-11-29 | Anticoagulant reversal agents |
| EP12806229.6A EP2785700B1 (en) | 2011-11-29 | 2012-11-29 | Anticoagulant reversal agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02424B true ME02424B (me) | 2016-09-20 |
Family
ID=47430065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-95A ME02424B (me) | 2011-11-29 | 2012-11-29 | Agensi koji vrše reverziju antikoagulanta |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9522892B2 (me) |
| EP (1) | EP2785700B1 (me) |
| JP (1) | JP6134731B2 (me) |
| KR (1) | KR101892330B1 (me) |
| CN (1) | CN104080772B (me) |
| AP (1) | AP2014007662A0 (me) |
| AR (1) | AR089020A1 (me) |
| AU (1) | AU2012345975B2 (me) |
| BR (1) | BR112014012892B1 (me) |
| CA (1) | CA2856540C (me) |
| CL (1) | CL2014001399A1 (me) |
| CO (1) | CO6990738A2 (me) |
| CR (1) | CR20140310A (me) |
| CY (1) | CY1117414T1 (me) |
| DK (1) | DK2785700T3 (me) |
| EA (1) | EA027603B1 (me) |
| EC (1) | ECSP14006696A (me) |
| ES (1) | ES2569674T3 (me) |
| HR (1) | HRP20160513T1 (me) |
| HU (1) | HUE027452T2 (me) |
| IL (1) | IL232788B (me) |
| ME (1) | ME02424B (me) |
| MX (1) | MX349514B (me) |
| PE (1) | PE20141295A1 (me) |
| PH (1) | PH12014501176B1 (me) |
| PL (1) | PL2785700T3 (me) |
| PT (1) | PT2785700E (me) |
| RS (1) | RS54738B1 (me) |
| SG (1) | SG11201402713WA (me) |
| SI (1) | SI2785700T1 (me) |
| SM (1) | SMT201600161B (me) |
| UA (1) | UA116336C2 (me) |
| WO (1) | WO2013082210A1 (me) |
| ZA (1) | ZA201404793B (me) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999690B2 (en) | 2013-11-08 | 2018-06-19 | Perosphere Pharmaceuticals Inc. | Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds |
| CN114456176B (zh) | 2016-03-28 | 2024-08-30 | 因赛特公司 | 作为tam抑制剂的吡咯并三嗪化合物 |
| KR102739325B1 (ko) | 2017-09-27 | 2024-12-09 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
| AU2018365257B2 (en) * | 2017-11-13 | 2021-05-13 | Maximum Fidelity Surgical Simulations, Inc. | Reconstitution of post mortem circulation, specialized methods and procedures |
| US11241438B2 (en) | 2018-06-29 | 2022-02-08 | Incyte Corporation | Formulations of an AXL/MER inhibitor |
| US11716989B2 (en) | 2019-04-16 | 2023-08-08 | Maximum Fidelity Surgical Simulations, LLC | Cadaver preservation systems and methods |
| US11915610B2 (en) | 2019-05-15 | 2024-02-27 | Maximum Fidelity Surgical Simulations, LLC | Cadaverous heart model |
| CN112010930B (zh) * | 2019-05-28 | 2022-08-02 | 首都医科大学 | Rgd修饰的五环哌嗪二酮及其制备和应用 |
| PH12022552347A1 (en) | 2020-03-06 | 2024-01-29 | Incyte Corp | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| JP2026511191A (ja) | 2023-03-24 | 2026-04-10 | シャンシー・ミコ・ファーマシューティカル・テクノロジー・カンパニー，リミテッド | 抗凝固逆転剤及びその製造方法、並びにその応用 |
| CN117624137A (zh) * | 2023-12-04 | 2024-03-01 | 中国药科大学 | 三嗪骨架小分子肝素逆转剂及其制备方法与用途 |
| US20250389737A1 (en) * | 2024-06-20 | 2025-12-25 | Instrumentation Laboratory Company | FACTOR Xa REAGENT |
| EP4667582A1 (en) * | 2024-06-20 | 2025-12-24 | Instrumentation Laboratory Company | Factor xa reagent |
| CN121622691A (zh) * | 2024-08-30 | 2026-03-10 | 陕西麦科奥特医药科技股份有限公司 | 使用抗凝逆转剂治疗抗凝剂导致的出血的方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3678157A (en) * | 1968-10-23 | 1972-07-18 | Oreal | Hair treatment compositions containing polycondensable compounds |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| US6069232A (en) * | 1995-10-02 | 2000-05-30 | Hoechst Marion Roussel, Inc. | Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors |
| US6080852A (en) | 1996-06-27 | 2000-06-27 | The Perkin-Elmer Corporation | 4,7-dichlororhodamine dyes |
| CA2268381A1 (en) | 1996-10-11 | 1998-04-23 | Cor Therapeutics, Inc. | Selective factor xa inhibitors |
| PL336233A1 (en) * | 1997-04-07 | 2000-06-19 | Axys Pharm Inc | Compounds and agents for treating diseases associated with serinic protease activity, in particular tryptase activity |
| FR2781221B1 (fr) * | 1998-07-17 | 2000-10-13 | Lafon Labor | Piperazinones substituees en alpha |
| CA2348740A1 (en) * | 1998-12-23 | 2000-07-06 | Ruth R. Wexler | Thrombin or factor xa inhibitors |
| CA2373610A1 (en) | 1999-05-19 | 2000-11-23 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| EP1377554A1 (en) | 1999-06-16 | 2004-01-07 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| JP2004501077A (ja) | 2000-04-17 | 2004-01-15 | ファルマシア・コーポレーション | 凝固カスケードの選択的阻害に有用な多環式アリールおよびヘテロアリール置換１，４−キノン |
| AU2001275857A1 (en) * | 2000-06-29 | 2002-01-14 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
| BR0213092A (pt) | 2001-10-03 | 2004-10-19 | Pharmacia Corp | Compostos heterocìclicos de 6 elementos úteis para a inibição seletiva da cascata de coagulação |
| AU2003217028A1 (en) | 2002-03-27 | 2003-10-13 | Cambridge University Technical Services Ltd | Diaminoacid-aminoacid-polyamine based gemini surfactant compounds |
| US20060233786A1 (en) * | 2002-05-23 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
| GB0214122D0 (en) | 2002-06-19 | 2002-07-31 | Eastman Kodak Co | High contrast photographic element containing a polyhydrazide nucleating agent |
| SE0400014D0 (sv) * | 2004-01-08 | 2004-01-08 | Astrazeneca Ab | Heterocyclic derivatives |
| US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| WO2008105441A1 (ja) * | 2007-02-27 | 2008-09-04 | Ajinomoto Co., Inc. | リン吸収抑制活性を有するポリアミノ酸化合物及びリン吸収抑制剤 |
| EP2193196B1 (en) * | 2007-09-28 | 2016-07-13 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| GB2476643B (en) | 2009-12-23 | 2012-11-14 | Haomamedica Ltd | 1,4-Dihydro-1,4-dioxonaphtalene derivatives as anticoagulants |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| PE20140964A1 (es) | 2011-03-30 | 2014-08-17 | Boehringer Ingelheim Int | Antidotos anticoagulantes |
-
2012
- 2012-11-29 WO PCT/US2012/066938 patent/WO2013082210A1/en not_active Ceased
- 2012-11-29 ME MEP-2016-95A patent/ME02424B/me unknown
- 2012-11-29 SI SI201230558A patent/SI2785700T1/sl unknown
- 2012-11-29 US US13/688,442 patent/US9522892B2/en active Active
- 2012-11-29 DK DK12806229.6T patent/DK2785700T3/en active
- 2012-11-29 PT PT128062296T patent/PT2785700E/pt unknown
- 2012-11-29 MX MX2014006349A patent/MX349514B/es active IP Right Grant
- 2012-11-29 EA EA201490823A patent/EA027603B1/ru unknown
- 2012-11-29 CA CA2856540A patent/CA2856540C/en active Active
- 2012-11-29 UA UAA201404997A patent/UA116336C2/uk unknown
- 2012-11-29 JP JP2014544857A patent/JP6134731B2/ja active Active
- 2012-11-29 EP EP12806229.6A patent/EP2785700B1/en active Active
- 2012-11-29 KR KR1020147016304A patent/KR101892330B1/ko active Active
- 2012-11-29 PE PE2014000763A patent/PE20141295A1/es active IP Right Grant
- 2012-11-29 HR HRP20160513TT patent/HRP20160513T1/hr unknown
- 2012-11-29 BR BR112014012892-8A patent/BR112014012892B1/pt active IP Right Grant
- 2012-11-29 HU HUE12806229A patent/HUE027452T2/en unknown
- 2012-11-29 PL PL12806229.6T patent/PL2785700T3/pl unknown
- 2012-11-29 RS RS20160318A patent/RS54738B1/sr unknown
- 2012-11-29 ES ES12806229.6T patent/ES2569674T3/es active Active
- 2012-11-29 SG SG11201402713WA patent/SG11201402713WA/en unknown
- 2012-11-29 AU AU2012345975A patent/AU2012345975B2/en active Active
- 2012-11-29 AR ARP120104474A patent/AR089020A1/es active IP Right Grant
- 2012-11-29 CN CN201280060950.2A patent/CN104080772B/zh active Active
- 2012-11-29 AP AP2014007662A patent/AP2014007662A0/xx unknown
-
2014
- 2014-05-26 PH PH12014501176A patent/PH12014501176B1/en unknown
- 2014-05-26 IL IL232788A patent/IL232788B/en active IP Right Grant
- 2014-05-27 CL CL2014001399A patent/CL2014001399A1/es unknown
- 2014-06-26 CO CO14137450A patent/CO6990738A2/es unknown
- 2014-06-26 CR CR20140310A patent/CR20140310A/es unknown
- 2014-06-26 EC ECIEPI20146696A patent/ECSP14006696A/es unknown
- 2014-06-27 ZA ZA2014/04793A patent/ZA201404793B/en unknown
-
2016
- 2016-04-25 CY CY20161100338T patent/CY1117414T1/el unknown
- 2016-06-08 SM SM201600161T patent/SMT201600161B/it unknown
- 2016-11-10 US US15/348,348 patent/US9877961B2/en active Active
-
2017
- 2017-10-06 US US15/726,497 patent/US20180207152A1/en not_active Abandoned
-
2020
- 2020-12-10 US US17/117,559 patent/US20210169874A1/en not_active Abandoned
-
2023
- 2023-12-15 US US18/541,391 patent/US20240366592A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534270A5 (me) | ||
| Rabbat et al. | Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency | |
| Lotke et al. | The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. | |
| Gouin-Thibault et al. | Safety profile of different low-molecular weight heparins used at therapeutic dose | |
| Lieberman et al. | Prevention of venous thromboembolic disease after total hip and knee arthroplasty | |
| Ansell et al. | Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin | |
| Agnelli et al. | Management of venous thromboembolism in patients with cancer | |
| Kragh et al. | Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth | |
| Antonelli et al. | Enoxaparin associated with huge abdominal wall hematomas: a report of two cases | |
| Siguret et al. | No accumulation of the peak anti‐factor Xa activity of tinzaparin in elderly patients with moderate‐to‐severe renal impairment: the IRIS substudy | |
| Jiang et al. | Comparison of apixaban and low molecular weight heparin in preventing deep venous thrombosis after total knee arthroplasty in older adults | |
| US20120322760A1 (en) | Methods of treatment with a low molecular weight heparin composition | |
| Schobess et al. | Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration | |
| US9700603B2 (en) | Use of antidotes to coagulation inhibitors indicated in the prevention or treatment of thromboembolic pathologies | |
| Song et al. | Fondaparinux versus nadroparin for thromboprophylaxis following minimally invasive esophagectomy: a randomized controlled trial | |
| Elbarouni et al. | Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes | |
| Arnold et al. | Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients | |
| CA2645982A1 (en) | Use of ave5026 for minimizing the incidence of bleedings during an antithrombotic treatment | |
| Crowther et al. | Thromboprophylaxis in medical–surgical critically ill patients | |
| Balla et al. | Intentional overdose with tinzaparin: management dilemmas | |
| Rico et al. | Safety assessment and pharmacodynamics of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers–a first-time-in-human single ascending dose study | |
| Poredos et al. | Deep vein thrombosis and pulmonary embolism in the apixaban era: from bench to bedside | |
| Mukhesh et al. | Incidence and factors associated with bleeding in critically ill medical patients on pharmacological prophylaxis for deep vein thrombosis in intensive care unit-a single-center observational study from South India. | |
| Comp | Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery | |
| Caprini et al. | Venous thrombosis prophylaxis |